| Date Filed | Type | Description |
| 10/06/2023 |
SC 13G
| First Light Asset Management, LLC reports a 10.3% stake in TELA Bio, Inc. |
| 09/28/2023 |
8-K
| Quarterly results |
| 08/16/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Investor presentation, Quarterly results |
| 08/04/2023 |
4
| Firestone Gregory A. (Chief Business Officer) has filed a Form 4 on TELA Bio, Inc.|
Txns:
| Granted 17,950 shares
@ $0 |
|
| 08/04/2023 |
3
| Firestone Gregory A. (Chief Business Officer) has filed a Form 3 on TELA Bio, Inc. |
| 06/02/2023 |
4
| O'Brien Federica F. (Director) has filed a Form 4 on TELA Bio, Inc.|
Txns:
| Granted 3,135 shares
@ $0
Granted 5,360 options to buy
@ $10.34, valued at
$55.4k
|
|
| 06/02/2023 |
4
| COLLERAN LISA N (Director) has filed a Form 4 on TELA Bio, Inc.|
Txns:
| Granted 3,135 shares
@ $0
Granted 5,360 options to buy
@ $10.34, valued at
$55.4k
|
|
| 06/02/2023 |
4
| EVANS DOUGLAS G (Director) has filed a Form 4 on TELA Bio, Inc.|
Txns:
| Granted 3,135 shares
@ $0
Granted 5,360 options to buy
@ $10.34, valued at
$55.4k
|
|
| 06/02/2023 |
4
| Azarbarzin Kurt (Director) has filed a Form 4 on TELA Bio, Inc.|
Txns:
| Granted 3,135 shares
@ $0
Granted 5,360 options to buy
@ $10.34, valued at
$55.4k
|
|
| 06/02/2023 |
4
| Nosenzo John (Director) has filed a Form 4 on TELA Bio, Inc.|
Txns:
| Granted 3,135 shares
@ $0
Granted 5,360 options to buy
@ $10.34, valued at
$55.4k
|
|
| 06/02/2023 |
4
| Burgess Vincent J (Director) has filed a Form 4 on TELA Bio, Inc.|
Txns:
| Granted 3,135 shares
@ $0
Granted 5,360 options to buy
@ $10.34, valued at
$55.4k
|
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Investor presentation, Quarterly results |
| 04/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/21/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/20/2023 |
8-K
| Quarterly results |
| 04/20/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 04/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/19/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/18/2023 |
8-K
| Quarterly results |
| 04/18/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 04/17/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/17/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/17/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/04/2023 |
4
| KOBLISH ANTONY (CEO) has filed a Form 4 on TELA Bio, Inc.|
Txns:
| Paid exercise price by delivering 385 shares
@ $10.64, valued at
$4.1k
|
|
| 04/04/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/04/2023 |
4
| Murphy Peter C. (Chief Commercial Officer) has filed a Form 4 on TELA Bio, Inc.|
Txns:
| Paid exercise price by delivering 163 shares
@ $10.64, valued at
$1.7k
|
|
| 04/04/2023 |
4
| Talmo Paul (Chief Strategic Officer) has filed a Form 4 on TELA Bio, Inc.|
Txns:
| Paid exercise price by delivering 187 shares
@ $10.64, valued at
$2k
|
|
| 03/31/2023 |
4
| Burgess Vincent J (Director) has filed a Form 4 on TELA Bio, Inc.|
Txns:
| Exercised 4,860 options to buy
@ $4.44, valued at
$21.6k
|
|
| 03/23/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/23/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
|